LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study

June 18
Last Trade: 48.44 6.39 15.20

Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured,...Read more


MindBio Therapeutics Enrols Final Participant in Phase 2B Depression Trial

June 18
Last Trade: 0.01 0.00 0.00

90th participant enrolled in landmark clinical trial in patients with Major Depressive Disorder  Targets October 2025 for initial results presentation  Vancouver, British Columbia – TheNewswire - June 18, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt:...Read more


Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

June 18
Last Trade: 0.08 0.005 6.67

Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of...Read more


Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients...

June 18
Last Trade: 68.27 -0.54 -0.78

Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) Patients with relapsed or refractory FL achieved significantly improved progression-free survival...Read more


Gilead Sciences: Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months...

June 18
Last Trade: 108.00 0.00 0.00

Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo Yeztugo, Nearly 20 Years in the Making, Represents a Major Breakthrough in the Fight Against HIV FOSTER CITY, Calif. / Jun 18, 2025 / Business Wire...Read more


FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s...

June 18
Last Trade: 2.29 -0.03 -1.29

FDA priority review and approval based on interim results sets a positive precedent, paving the path for future Multikine approval Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk...Read more


Featured Stock

Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Vertex Pharmaceuticals 6.41 1.45 $448.40
GRAIL 6.39 15.20 $48.44
Scholar Rock 5.17 16.60 $36.32
Bolt Biotherapeutics 5.10 912.52 $5.66
United Therapeutics 4.84 1.69 $291.72
Medpace 4.77 1.60 $302.69
Regeneron Pharmaceuticals 4.72 0.93 $513.58
McKesson 4.53 0.63 $728.91
Quantum BioPharma 4.47 17.37 $30.20
HCA Healthcare 4.41 1.18 $376.86
National HealthCare 4.20 4.12 $106.04
Alnylam Pharmaceuticals 3.61 1.17 $312.32
Nutex Health 3.50 3.03 $119.00
Masimo 3.45 2.17 $162.77
Natera 3.43 2.05 $170.98
Semler Scientific 3.41 11.95 $31.94
Madrigal Pharmaceuticals 3.12 1.12 $282.72
Molina Healthcare 2.94 1.01 $295.34

Highest Volume

 
CompanyVolumeLast Trade
Healthcare Triangle 431,572,371 $0.03
Aptevo Therapeutics 123,560,236 $5.00
Helius Medical Technologies 66,828,404 $0.37
NuCana 60,711,935 $0.12
Biodexa Pharmaceuticals 54,444,180 $1.03
Oscar Health 48,126,255 $18.82
Pfizer 35,432,789 $23.88
34,891,557 $5.11
Incannex Healthcare 30,820,978 $0.22
Azitra 27,859,804 $0.26
GeoVax Labs 25,570,430 $0.93
Plus Therapeutics 23,046,548 $0.21
Biomea Fusion 21,079,287 $1.91
Merck 19,610,577 $79.29
PacBio 19,507,367 $1.31
Proces Pharmaceuticals 18,494,752 $0.25
bioAffinity Technologies 18,074,390 $0.25
Bristol-Myers Squibb 15,303,078 $46.80
Immuneering 13,167,131 $2.77
  • Upcoming FDA Catalysts

    • Merck (NYSE: MRK) PDUFA Date

      June 23, 2025
    • Regeneron Pharmaceuticals (NASDAQ: REGN) PDUFA Date

      July 10, 2025
    • Ascendis Pharma (NASDAQ: ASND) PDUFA Date

      July 27, 2025
    • Apellis Pharmaceuticals (NASDAQ: APLS) PDUFA Date

      July 28, 2025
    • Regeneron Pharmaceuticals (NASDAQ: REGN) PDUFA Date

      July 30, 2025
    • Tonix Pharmaceuticals (NASDAQ: TNXP) PDUFA Date

      August 15, 2025

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Surmodics

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:
Edit